Algocyte gives NHS oncology teams earlier visibility into haematological toxicity, reducing avoidable admissions and protecting treatment continuity.
Scheduled CBCs and outpatient appointments make monitoring intermittent, not regular.
Toxicity is identified after the patient has already deteriorated.
Repeated visits, blood draws and nursing time the service cannot spare.
At-home CBC testing on Algocyte Proxima, AI risk stratification and automated alerts surface deterioration earlier, so the team intervenes in clinic, not in A&E.
Inside Health HubLongitudinal patient intelligence across regular CBC monitoring keeps patients on the protocol that's working, and gives the team a defensible record of why decisions were made.
Meet ProximaEarlier detection of haematological toxicity reduces emergency admissions.
Keeps regular CBC monitoring out of acute settings and inside the patient's home.
Replaces phone follow-up with longitudinal, structured clinical data.
Designed against NHS digital, clinical safety and information-governance standards.
Book a 20-minute briefing with our clinical team to see Algocyte in action.